Isoenzyme der Kreatinkinase bei extrakardialen Erkrankungen und nach diagnostischen und therapeutischen Eingriffen

Prellwitz, W.; Neumeier, D.; Knedel, M.; Lang, Hermann; Würzburg, U.; Schönborn, H.; Schuster, H.-P.

doi:10.1055/s-0028-1104201

Cited by 34 publications

(13 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This is probably due to the fact that in the majority of the conditions studied (i.e. head injuries, cerebrovascular disease, tumours, meningitis), central nervous system (CNS) involvement is widespread and/or massive, and thus no conclusion about the pathogene sis of these conditions can be reached [1][2][3][4][5][6][7][8].…”

mentioning

confidence: 99%

Serum Creatine Kinase B Levels in Diseases of the Central Nervous System

Vassilopoulos¹,

Jockers-Wretou²

1987

Eur Neurol

View full text Add to dashboard Cite

The creatine kinase B (CK-B) subunit was determined by our own highly sensitive solid-phase direct immunoassay in three neurological diseases which represent models of central nervous system (CNS) involvement: (1) idiopathic epilepsy (18 patients), a disease characterised by a transient neuronal hyperactivity; (2) Parkinson’s disease (17 patients), a degenerative disorder of the CNS, and (3) multiple sclerosis (21 patients), which represents a model of demyelination of the CNS. A group of 50 controls was also studied. The results showed that in patients with epilepsy and multiple sclerosis the CK-B activity was considerably lower than in the controls (p < 0.01 and p < 0.005, respectively), while no differences were found between the controls and the patients with Parkinson’s disease. It is suggested that the low CK-B activity observed might be due to the medication taken or to the disease process itself. The present findings have to be considered as an indication for further CK isoenzyme studies in systematic disorders of the nervous system.

show abstract

mentioning

confidence: 99%

Serum Creatine Kinase B Levels in Diseases of the Central Nervous System

Vassilopoulos¹,

Jockers-Wretou²

1987

Eur Neurol

View full text Add to dashboard Cite

show abstract

“…In the study reported here, we made the first attempt to detect possible myocardial damage resulting from fairly long-term treatment with a /3-adrenergic drug using an objective biochemical parameter, that is to say measuring creatine kinase MB activity. This creatine kinase isoenzyme is of proven sensitivity (7,9,10,15). The results show that there is evidently no necrosis-type myocardial damage even with long-term tocolytic treatment with the relatively high dosage of 0.24 mg fenoterol/h.…”

Section: Discussionmentioning

confidence: 99%

“…This is done by measuring the activity of the isoenzyme of creatine kinase, creatine kinase MB, which, to a large extent, is specific to heart muscle (7,12,15). This technique is just as reliable as the ECG for indicating myocardial necrosis (9,10,15).…”

mentioning

confidence: 99%

Study to Confirm the Lack of Severe Cardiac Side-Effects following Treatment with the Beta-Adrenergic Drug Fenoterol

Meinen¹,

Breinl²,

Schmidt³

et al. 1978

Gynecol Obstet Invest

View full text Add to dashboard Cite

100 patients with premature contractions were treated with the Β-adrenergic agent fenoterol for up to 9 weeks. To rule out a detrimental effect on the myocardium, the creatine kinase isoenzym MB, which is specific to the myocardium, was determined regulary in addition to electrocardiographic monitoring. No pathological enzyme activity was detected even in long-term tocolytic therapy with the maximum dose.

show abstract

“…Höhere Aktivitäten entsprechen einer pathologischen Kreatinkinase-MB-Aktivität. Dieser Grenzwert stimmt mit den für die Kreatinkinase-MB (GSH-aktiviert) mitgeteilten Befunden (10,13), die inzwischen vielfach über-prüft wurden (9,17,(21)(22)(23)(24)(25) …”

Section: Kreatinkinase-mb -Entscheidungsgrenzeunclassified

“…und Alanin-aminotransferase, -Glutamyltransferase undHydroxybutyratdehydrogenase sowie der Kreatinkinase (GSHaktiviert, (3)) und ihres Isoenzyms MB (GSH-aktiviert, (10)). Bei 66 Patienten mit klinisch und elektrokardiographisch gesichertem, aktutem, trahsmuralem Myokardinfarkt (14) wurde die Aktivität der Kreatinkinase (359 Messungen, jeweils GSHund N-Acetylcystein-aktiviert) und der Kreatinkinase-MB (293 Messungen, jeweils GSH-und N-Acetylcystein-aktiviert) gemessen.…”

unclassified

Kreatinkinase und Kreatinkinase-Isoenzym MB: Erfahrungen mit der neuen Optimierten Methode mit N-Acetylcystein als Aktivator bei Gesunden und bei akutem Myokardinfarkt

Schmidt¹,

Bender²

1979

Clinical Chemistry and Laboratory Medicine

View full text Add to dashboard Cite

Zusammenfassung: Es wird über erste Ergebnisse mit der N-Acetylcystein-aktivierten Kreatinkinase und ihrem Isoenzym MB bei Gesunden und bei Patienten mit akutem, transmuralem Myokardinfarkt berichtet. Bei Gesunden betrug die obere Normgrenze der Kreatinkinaseaktivität 54 U/l, die Entscheidungsgrenze für das Vorliegen einer Kre^tin-kinase-MB-Aktivität lag bei 9 U/l. Den nur wenig differenten Grenzwerten im Vergleich zur GSH-aktivierten Kreatinkinase entspricht ein linearer Zusammenhang mit einem Steigungsfaktor nahe l ,0 zwischen den Ergebnissen mit den alten und den neuen Methoden. Die unterschiedliche Reaktivierbarkeit von Kreatinkinase-MM durch GSH und NAcetylcystein wird diskutiert; eine Umrechnung der Aktivitäten von Kreatinkinase und Kreatinkinase-MB von der GSH-aktivierten Methode in die N-Acetylcystein-aktivierte Methode ist nicht möglich. Creatine kinase and creatine kinase isoenzymeMB: Determination of normal values and values for myocardial infarct, using the new, optimized method with N-acetyl cysteine as the activatorSummary: Preliminary results are reported for the determination of creatine kinase and its isoenzyme MB in healthy individuals and in patients with acute, transmural myocardial infarct, using N-acetyl cysteine as the activator of the enzyme. In healthy individuals, the upper normal limit for creatine kinase activity was 54 U/l; the decision level for the presence of creatine kinase MB activity 9 U/l. The limiting values were only slightly different from those for the GSH-activated creatine kinase, and the results with the old and new methods showed a linear relationship with a slope of .0. The differences in the activation of creatine kinase MM by GSH and by N-acetyl cysteine are discussed; the activities obtained for creatine kinase and creatine kinase-MB by the GSH-activation method cannot simply be recalculated to give the appropriate values for the N-acetyl cysteine activation method. Einleitungden kann (5), entspricht die Einführung der neuen, optiDie Messung der Kreatinkinase (ATP: Kreatin-N-Phospho-<^6 Reaktionsbedingungen bei dem Kreatinkinasetransferase; EC 2.7.3.2) kann durch verschiedene Einflüsse MB-Test*) ™™ dringenden Bedürfnis. In der vorliegengestört werden (1-5). Fehlbestimmungen durch die An-** Arbeit wird über erste Ergebnisse mit der N-AcetylWesenheit von Adenylatkinase (ATP:-Phosphptrans-cystein-aktivierten Kreatinkinase und dem Isoenzym MB ferase; EC 2.7.4.3) aus Lebergewebe oder Erythrocyten bei Gesunden und bei Infarktpatienten berichtet,

show abstract

Isoenzyme der Kreatinkinase bei extrakardialen Erkrankungen und nach diagnostischen und therapeutischen Eingriffen

Cited by 34 publications

References 0 publications

Serum Creatine Kinase B Levels in Diseases of the Central Nervous System

Serum Creatine Kinase B Levels in Diseases of the Central Nervous System

Study to Confirm the Lack of Severe Cardiac Side-Effects following Treatment with the Beta-Adrenergic Drug Fenoterol

Kreatinkinase und Kreatinkinase-Isoenzym MB: Erfahrungen mit der neuen Optimierten Methode mit N-Acetylcystein als Aktivator bei Gesunden und bei akutem Myokardinfarkt

Contact Info

Product

Resources

About